niacinamide has been researched along with oxonic acid in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 10 (83.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Von Hoff, DD | 1 |
Hampton, T | 1 |
Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T | 1 |
Katsahian, S; O'Quigley, J; Zohar, S | 1 |
Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ | 1 |
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y | 1 |
Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O | 1 |
Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J | 1 |
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y | 1 |
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
1 review(s) available for niacinamide and oxonic acid
Article | Year |
---|---|
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
4 trial(s) available for niacinamide and oxonic acid
Article | Year |
---|---|
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome | 2012 |
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur | 2014 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2015 |
7 other study(ies) available for niacinamide and oxonic acid
Article | Year |
---|---|
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur | 2007 |
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur | 2011 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase | 2011 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase | 2013 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2014 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |